🇺🇸 Ribavirin Capsules in United States

30 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 28 March 2025 – 28 March 2026
• Total reports: 30

Most-reported reactions

1. Fatigue — 5 reports (16.67%)
2. Nausea — 4 reports (13.33%)
3. Asthenia — 3 reports (10%)
4. Exposure Via Father — 3 reports (10%)
5. Foetal Exposure During Pregnancy — 3 reports (10%)
6. Maternal Exposure During Pregnancy — 3 reports (10%)
7. Vomiting — 3 reports (10%)
8. Abortion Spontaneous — 2 reports (6.67%)
9. Anaemia — 2 reports (6.67%)
10. Anger — 2 reports (6.67%)

Source database →

Frequently asked questions

Is Ribavirin Capsules approved in United States?

Ribavirin Capsules does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Ribavirin Capsules in United States?

The Scientific and Technological Research Council of Turkey is the originator. The local marketing authorisation holder may differ — check the official source linked above.